Skip to content
value.today

Obsidian Therapeutics, Inc.

OBX
No market cap data
Compare
World rank
—
no current market cap
Revenue
—
For year ending December-2025
Net income
$-101 M
SEC filing
Employees
—

Obsidian Therapeutics, Inc. in brief

Obsidian Therapeutics, Inc. is a listed company in the Biotechnology industry, based in Cambridge, Massachusetts, USA. Its shares trade under the symbol OBX (Nasdaq).

Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.

Obsidian Therapeutics, Inc. timeline

2 events, 2026
  1. 2026
  2. •
    · approximate
    First filing with the US SEC
    The company's first electronic filing in SEC EDGAR.
  3. ✎
    Renamed Obsidian Therapeutics, Inc.
    Formerly Gazelle Parent, Inc..

Events of Obsidian Therapeutics, Inc. from SEC EDGAR. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.

Market cap history

Not enough history yet.

Financial history

USD · fiscal years · source: SEC filings
RevenueNet income
Fiscal year ending Dec 2024: revenue —, net income $-83M—FY24Fiscal year ending Dec 2025: revenue —, net income $-101M—FY25
Fiscal year endingRevenueGrowthOperating incomeNet incomeNet margin
Dec 2025——$-106M$-101M—
Dec 2024——$-91M$-83M—

Cash flow, debt and per share

Fiscal year endingOperating cash flowCapital spendingFree cash flowEPS (diluted)Dividend / share
Dec 2025$-90M$0M$-90M$-7.22—
Dec 2024$-75M$1M$-76M$-6.47—

Quarterly results

USD · three months to · source: SEC filings
RevenueNet income
Three months to Mar 2025: revenue —, net income $-25M—Mar ’25Three months to Jun 2025: revenue —, net income $-27M—Jun ’25Three months to Sep 2025: revenue —, net income $-28M—Sep ’25Three months to Dec 2025 (from the annual report): revenue —, net income $-20M—Dec ’25Three months to Mar 2026: revenue —, net income $-20M—Mar ’26Three months to Jun 2026: revenue —, net income $-26M—Jun ’26Three months to Sep 2026: revenue —, net income $-51M—Sep ’26

Latest quarter to Sep 2026: revenue —, net income $-51M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.

SEC filings

Official filings of Obsidian Therapeutics, Inc. with the US Securities and Exchange Commission.

Annual results

Revenue
—
Operating income
$-106 M
Net income
$-101 M

For year ending December-2025 · source: SEC filing

Balance sheet

Total assets
$89 M
Total liabilities
$17 M
Total equity
$-266 M

As of December-2025

Top 60 institutional investors in Obsidian Therapeutics, Inc.#

As of Sep 30, 2026
60 institutions held 50.6 M shares (about 82.0% of the shares outstanding) on Sep 30, 2026. The ten largest hold 50.8%. Source: SEC Form 13F filings, filed through Nov 16, 2026. Change is since the previous quarter.This quarter is still being filed: about 99% of the institutions that reported last quarter have filed so far. Institutions that have not filed yet are missing from the list, not sellers; the list is brought up to date every day.
The 25 largest institutional investors in Obsidian Therapeutics, Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
1Ra Capital Management, L.P.5,957,103New9.64%$82 MNov 16, 2026
2Atlas Venture Life Science Advisors, LLC4,503,149New7.29%$62 MNov 10, 2026
3Paradigm Biocapital Advisors LP4,155,214New6.73%$57 MNov 16, 2026
4Novo Holdings A/s3,123,992New5.06%$43 MNov 16, 2026
5Trails Edge Capital Partners, LP2,495,660New4.04%$34 MNov 16, 2026
6Vanguard Capital Management LLC2,441,332New3.95%$34 MNov 13, 2026
7Octagon Capital Advisors LP2,414,610New3.91%$33 MNov 16, 2026
8TCG Crossover Management, LLC2,196,138New3.56%$30 MNov 16, 2026
9Deep Track Capital, LP2,120,050New3.43%$29 MNov 16, 2026
10Citadel Advisors LLC1,947,843New3.15%$27 MNov 16, 2026
11Blue Owl Capital Holdings LP1,482,767New2.40%$20 MNov 13, 2026
12Spruce Street Capital LP1,249,943New2.02%$17 MNov 13, 2026
13Alphabet Inc.1,224,869New1.98%$17 MNov 6, 2026
14Nantahala Capital Management, LLC1,199,796New1.94%$16 MNov 13, 2026
15Price T Rowe Associates Inc /MD/1,057,455New1.71%$15 MNov 16, 2026
16Nan Fung Group Holdings Ltd918,765New1.49%$13 MNov 13, 2026
17Foresite Capital Management VI LLC916,063New1.48%$13 MNov 16, 2026
18Caligan Partners LP886,281New1.43%$12 MNov 16, 2026
19Pivotal bioVenture Partners Investment Advisor LLC860,343New1.39%$12 MNov 13, 2026
20Samsara Biocapital, LLC837,173New1.36%$11 MNov 16, 2026
21Redmile Group, LLC833,157New1.35%$11 MNov 16, 2026
22BlackRock, Inc.775,759New1.26%$11 MNov 13, 2026
23Janus Henderson Group Ltd.728,700—1.18%$10 MNov 16, 2026
24Eventide Asset Management, LLC624,972New1.01%$9 MNov 13, 2026
25Balyasny Asset Management L.P.587,724New0.95%$8 MNov 16, 2026
Show all 60: investors 26 to 60
Institutional investors 26 to 60 in Obsidian Therapeutics, Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
26Longaeva Partners L.P.499,963New0.81%$7 MNov 16, 2026
27Geode Capital Management, LLC483,438New0.78%$7 MNov 6, 2026
28Revelation Capital Management, LLC428,346New0.69%$6 MNov 2, 2026
29Kalehua Capital Management LLC416,649New0.67%$6 MNov 13, 2026
30Adage Capital Partners GP, L.L.C.416,648New0.67%$6 MNov 16, 2026
31Woodline Partners LP354,064New0.57%$5 MNov 16, 2026
32Ally Bridge Group (NY) LLC302,449New0.49%$4 MNov 16, 2026
33Charles Schwab Investment Management Inc301,706New0.49%$4 MNov 16, 2026
34Vanguard Fiduciary Trust Co291,071New0.47%$4 MNov 13, 2026
35State Street Corp223,487New0.36%$3 MNov 12, 2026
36UBS Group AG199,207New0.32%$3 MNov 10, 2026
37Millennium Management LLC165,336New0.27%$2 MNov 16, 2026
38Ikarian Capital, LLC158,942New0.26%$2 MNov 16, 2026
39Boothbay Fund Management, LLC141,651New0.23%$2 MNov 16, 2026
40TD Asset Management Inc140,520New0.23%$2 MNov 13, 2026
41Alyeska Investment Group, L.P.125,008New0.20%$2 MNov 16, 2026
42Northern Trust Corp102,524New0.17%$1 MNov 16, 2026
43Opaleye Management Inc.75,755New0.12%$1 MNov 16, 2026
44RTW Investments, LP67,706New0.11%$1 MNov 16, 2026
45Seven Grand Managers, LLC52,000New0.08%$1 MNov 16, 2026
46Goldman Sachs Group Inc42,912New0.07%$1 MNov 16, 2026
47GTS Securities LLC29,122New0.05%$0 MNov 16, 2026
48Aster Capital Management (DIFC) Ltd26,236New0.04%$0 MNov 12, 2026
49Seven Fleet Capital Management LP23,077New0.04%$0 MNov 16, 2026
50Vanguard Global Advisers, LLC17,175New0.03%$0 MNov 13, 2026
51Bank of New York Mellon Corp11,163New0.02%$0 MNov 5, 2026
52Tower Research Capital LLC (TRC)1,563New0.00%$0 MNov 16, 2026
53Morgan Stanley629New0.00%$0 MNov 13, 2026
54Citigroup Inc419New0.00%$0 MNov 4, 2026
55Toronto Dominion Bank351New0.00%$0 MNov 16, 2026
56Nuveen, LLC209New0.00%$0 MNov 10, 2026
57Strategic Financial Concepts, LLC125New0.00%$0 MNov 16, 2026
58Group One Trading LLC26New0.00%$0 MNov 10, 2026
59Danske Bank A/s1New0.00%$0 MNov 9, 2026
60SBI Securities Co., Ltd.1New0.00%$0 MOct 22, 2026

Markets and events: Obsidian Therapeutics, Inc.#

Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.

Short interest, 2026-10-30
1.2 M
61.5% of shares · 3.94 days to cover
Reg SHO threshold list
2 days
in the last 90 days
Shares sold short, last 6 reportsAll stocks →

Trading halts

  • 2026-08-17 13:30 UTC, code LUDP, resumed 13:40 UTC
  • 2026-08-13 15:00 UTC, code LUDP, resumed 15:05 UTC
  • 2026-08-13 14:33 UTC, code LUDP, resumed 14:43 UTC
  • 2026-08-10 15:09 UTC, code LUDP, resumed 15:19 UTC
  • 2026-08-05 13:49 UTC, code LUDP, resumed 13:59 UTC

Fails to deliver

  • : 1,044 shares at $14.52
  • : 648 shares at $14.59
  • : 492 shares at $13.86
  • : 474 shares at $13.93
  • : 1,230 shares at $13.25

Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables

Obsidian Therapeutics, Inc. scorecard#

Passes 1 of the 4 checks that could be worked out. Fiscal year 2025.

  • Valuationnot known
    • –P/E below its peers' medianNo market cap.
    • –Price to book below its peers' medianNo market cap.
    • –Price to sales below its peers' medianNo market cap.
    • –Free cash flow yield above 5%No market cap.
    • –Earnings yield above the 10-year Treasury yieldNo market cap.
    • –The price assumes slower growth than the last three years'No market cap.
  • Growth0 of 1
    • –Revenue grew in the newest yearRevenue of the year before is not on file.
    • –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
    • –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
    • ✗Earnings per share grew in the newest year-7.22 vs -6.47Diluted EPS -7.22 in fiscal 2025 against -6.47 the year before (report's currency).
    • –Net income higher than five years earlierNet income of five years earlier is not on file.
    • –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
  • Profitability0 of 1
    • ✗Profitable in the newest year-$101 MNet income -$101 M in fiscal 2025.
    • –Profitable in each of the last five yearsFive years of net income are not on file.
    • –Operating margin above its peers' medianNo operating margin on file.
    • –Return on equity above 15%No return on equity (equity missing or negative).
    • –Return on invested capital above 10%No return on invested capital on file.
    • –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
  • Financial health1 of 1
    • ✓Short-term assets cover short-term liabilities5.3×Current ratio 5.31 at the end of fiscal 2025.
    • –Debt below equityDebt or equity is not on file (or equity is negative).
    • –Net debt below three years of EBITDANet debt to EBITDA is not on file.
    • –Operating income covers interest five timesInterest expense is not on file.
    • –Cash from operations positive in each of the last three yearsThree years of operating cash flow are not on file.
    • –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
  • Shareholder returns0 of 1
    • –Pays a dividendDividends are not on file.
    • –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
    • –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
    • ✗Share count up no more than 2% in a year8.5%Diluted shares up 8.5% in fiscal 2025.
    • –Dividends and buybacks above 3% of the market valueNo market cap.
    • –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.

Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap (too old for the valuation checks, which need one at most 60 days old). A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

Events at Obsidian Therapeutics, Inc.#

What the company reported to the SEC within four business days (Form 8-K), newest first.

Warning signs in the last three years

  • Auditor changedFiling

Auditor changed 1 · Change in control 1 · Acquisition or sale completed 1 · Directors and officers 1 · Material agreement 1 · Unregistered share sale 1 · Shareholder rights changed 1 · Bylaws or fiscal year changed 1 · Results announced 2

Obsidian Therapeutics, Inc.: events reported to the SEC
FiledWhat happenedFiling
Results announced8-K
Auditor changedChange in controlAcquisition or sale completedDirectors and officersMaterial agreementUnregistered share saleShareholder rights changedBylaws or fiscal year changedResults announced8-K

Source: SEC EDGAR, Form 8-K item numbers · as of Nov 12, 2026

H-1B hiring at Obsidian Therapeutics, Inc.#

5 labor condition applications certified in fiscal 2026 for 5 positions, at a median wage of $110 K a year.

Certified, FY2026
5
#1,150 among companies on value.today
Worker positions
5
Median wage offered
$110 K
a year, full-time
Applications filed
5
Obsidian Therapeutics, Inc.: most frequent H-1B job titles in fiscal 2026
Job titlePositionsMedian wage offered
Associate Scientist, Cell TherapyMolecular and Cellular Biologists2$107 K
Associate Scientist, Analytical DevelopmentMedical Scientists, Except Epidemiologists1$110 K
Scientist, Viral Vector Analytical DevelopmentMolecular and Cellular Biologists1$135 K
Senior QA Operations ManagerRegulatory Affairs Specialists1$142 K

Where: Bedford, MA 2 · Cambridge, MA 2 · Downington, PA 1

Obsidian Therapeutics, Inc.: labor condition applications by fiscal year
Fiscal yearCertifiedPositionsMedian wageFiled
FY202655$110 K5
FY202533$110 K3
FY202333$89 K3
FY202222$135 K2
FY202111$180 K1

Source: US Department of Labor, LCA disclosure data. An application is not a visa: USCIS decides each petition later, and the yearly lottery limits new H-1B visas. Filed as Obsidian Therapeutics, Inc.

Peer comparison · Biotechnology

CompanyMarket capP/ENet marginRev. growth
Obsidian Therapeutics, Inc.🇺🇸————
Novo Nordisk A/S🇩🇰$203.2 B13.1×33.1%+10.8%
Vertex Pharmaceuticals Incorporated🇺🇸$134.3 B33.8×30.7%+8.9%
Moderna, Inc.🇺🇸$90.1 B—-110.5%-39.9%
Regeneron Pharmaceuticals, Inc.🇺🇸$84.1 B17.5×28.5%+1.0%
Argenx SE🇳🇱$52.8 B40.9×31.1%+89.9%
CSL Limited🇦🇺$51.6 B—-16.4%—
Samsung Biologics Co., Ltd.🇰🇷$51.5 B40.5×39.2%—
UCB SA🇧🇪$48.6 B26.3×20.1%+31.1%

P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.

Questions, comparisons and similar companies#

Sources and freshness

Annual results:
For year ending December-2025
Balance sheet:
As of December-2025
Profile updated:
Nov 16, 2026

Figures from SEC filing, value.today research; financial statements from SEC filings.

How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.

Work at Obsidian Therapeutics, Inc.? Verify and update this profile — free

Use your work e-mail address (on the company's own domain if possible). Fill in only what is new or missing; a link to where the figures are published (annual report, press release) speeds up the review.

Show Obsidian Therapeutics, Inc.'s ranking on your website Get the badge
Badge preview

The badge updates itself as the ranking changes.

Something wrong or missing about Obsidian Therapeutics, Inc.? Suggest a correction